Endoleaks Type II: no association with mortality

Original Title: Risk factors and consequences of persistent type II endoleaks. Reference: Ruby C. Lo et al. J Vasc Surg 2016;63:895-901

 

The presence of type II endoleaks is infrequent (1%-10%) and most cases resolve spontaneously at 12 months. When they don’t, there is still controversy as to whether they may be associated to aneurysm diameter increase or to aneurysm rupture requiring intervention or conversion to surgery.

2367 patients receiving endovascular aneurysm repair were analyzed; 1977 (84%) did not present leaks or presented transient endoleaks, and 390 patients presented persistent endoleaks at follow up.

There were no differences in anatomical characteristics of aneurysms between those with endoleaks and those without.

There were no difference in device type, but there was a higher rate of type II endoleaks with coil embolization to one or both hypogastric arteries (12% vs. 8% p=0.02) and also a higher rate of endoleaks when using extensions (12% vs. 8% (p=0.008).

Follow up was at mean 463 days and the presence of type II endoleaks was a predictor of reintervention (OR 15.3; CI 95% 9.7-24.3; p<0.01) but not of mortality (OR 1.1; CI 95% 0.9-1.6; p=0.477).

Conclusion
The presence of type II endoleaks in patients undergoing endovascular aneurysm repair to treat an abdominal aortic aneurysm is more frequent when there is coil embolization to one or both hypogastric arteries and when using extensions. Type II endoleak persistence is associated to an increase in reintervention but not to aneurysm rupture or mortality. This reinforces the need to control patients with type II endoleak persistence.

Editorial Comment
Though retrospective, and therefore weak, this is the largest study on type II endoleaks. Even so, it seems clear that type II endoleaks are not associated with hard events such as death or rupture.

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...